Competitive group I metabotropic glutamate receptor antagonist, with selectivity for mGlu1a/1a over mGlu5a/5b.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|1eq. NaOH||19.52||100mM with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 195.17. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||5.12 mL||25.62 mL||51.24 mL|
|5 mM||1.02 mL||5.12 mL||10.25 mL|
|10 mM||0.51 mL||2.56 mL||5.12 mL|
|50 mM||0.1 mL||0.51 mL||1.02 mL|
References are publications that support the products' biological activity.
Birse et al (1993) Phenylglycine derivatives as new pharmacological tools for investigating the role of metabotropic glutamate receptors in the central nervous system. Neuroscience 52 481 PMID: 7680790
Brabet et al (1995) Phenylglycine derivatives discriminate between mGluR1-and mGluR5-mediated responses. Neuropharmacology 34 895 PMID: 8532171
Doherty et al (1999) Antagonist activity of α-substituted 4-carboxyphenylglycine analogues at group I metabotropic glutamate receptors expressed in CHO cells. Br.J.Pharmacol. 126 205 PMID: 10051137
Eaton et al (1993) Competitive antagonism at metabotropic glutamate receptors by (S)-4-carboxyphenylglycine (CPG) and (RS)-α-methyl-4-carboxyphenylglycine (MCPG). Eur.J.Pharmacol. 244 195 PMID: 8381746
If you know of a relevant reference for (S)-4-Carboxyphenylglycine, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: (S)-4-Carboxyphenylglycine, supplier, competitive, Group, I, mGlur, antagonists, weak, group, II, agonists, Competitive, Receptors, mGlu2, mGlu3, mGluR2, mGluR3, Glutamate, Metabotropic, mGlu1, mGlu5, mGluR1, mGluR5, (S)-4CPG, Glutamate, (Metabotropic), Group, I, Receptors, Glutamate, (Metabotropic), Group, II, Receptors, Glutamate, (Metabotropic), Group, I, Receptors, Tocris Bioscience
6 Citations for (S)-4-Carboxyphenylglycine
Citations are publications that use Tocris products. Selected citations for (S)-4-Carboxyphenylglycine include:
Griffin et al (2015) Repeated cycles of chronic intermittent ethanol exposure increases basal glutamate in the nucleus accumbens of mice without affecting glutamate transport. Front Pharmacol 6 27 PMID: 25755641
Resch et al (2014) Augmented cystine-glutamate exchange by pituitary adenylate cyclase-activating polypeptide signaling via the VPAC1 receptor. Synapse PMID: 25066643
Mahler et al (2014) Modafinil attenuates reinstatement of cocaine seeking: role for cystine-glutamate exchange and metabotropic glutamate receptors. J Young Investig 19 49 PMID: 23017017
Overocker and Pfau (2012) Cytokine Production Modified by System X(c)- After PM10 and Asbestos Exposure. Proc Natl Acad Sci U S A 23 34 PMID: 23418405
Liu et al (2007) Cystine-glutamate transporter SLC7A11 mediates resistance to geldanamycin but not to 17-(allylamino)-17-demethoxygeldanamycin. Mol Pharmacol 72 1637 PMID: 17875604
Porter et al (2005) Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther 315 711 PMID: 16040814
Do you know of a great paper that uses (S)-4-Carboxyphenylglycine from Tocris? If so please let us know.
Reviews for (S)-4-Carboxyphenylglycine
There are currently no reviews for this product. Be the first to review (S)-4-Carboxyphenylglycine and earn rewards!
Have you used (S)-4-Carboxyphenylglycine?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.